Review article: the role of non‐biological drugs in refractory inflammatory bowel disease

Background  Up to one‐third of patients with inflammatory bowel disease (IBD) do not respond to, or are intolerant of conventional immunosuppressive drugs. Although biological agents are alternative treatments, they may not be suitable or available to some patients.

[1]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[2]  G. Fiorino,et al.  New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. , 2010, Current medicinal chemistry.

[3]  M. Jiang,et al.  Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. , 2010, World journal of gastroenterology.

[4]  J. Sanderson,et al.  Low‐dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[5]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[6]  T. Matsui,et al.  An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment , 2009, The American Journal of Gastroenterology.

[7]  A. Sood,et al.  The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  S. McCartney,et al.  Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine , 2009, Alimentary pharmacology & therapeutics.

[9]  M. Schwartz,et al.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[10]  R. Gearry,et al.  Biologics for inflammatory bowel diseases in the Asia–Pacific: Can we afford to use them, can we afford not to? , 2009, Journal of gastroenterology and hepatology.

[11]  H. Sokol,et al.  Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? , 2009, Gastroenterologie clinique et biologique.

[12]  E. Kuipers,et al.  Local application of tacrolimus in distal colitis: Feasible and safe , 2009, Inflammatory bowel diseases.

[13]  A. Bitton,et al.  Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double‐blind, placebo‐controlled pilot study , 2009, Inflammatory bowel diseases.

[14]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[15]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[16]  W. Sandborn,et al.  An Update on the Epidemiology of Inflammatory Bowel Disease in Asia , 2008, The American Journal of Gastroenterology.

[17]  J. Sanderson,et al.  Long‐term outcome of using allopurinol co‐therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[18]  T. Chiba,et al.  Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis , 2008, Alimentary pharmacology & therapeutics.

[19]  T. Hibi,et al.  Randomized , Double-Blind , Sham-Controlled Study of ranulocyte / Monocyte Apheresis for Active Ulcerative Colitis , 2008 .

[20]  P. Gibson,et al.  A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: A case for subcutaneous administration , 2008, Journal of gastroenterology and hepatology.

[21]  J. Berg,et al.  Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. , 2008, Pharmacogenomics.

[22]  E. Bloemena,et al.  Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  A. Buchman,et al.  Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: A single‐center experience , 2008, Inflammatory bowel diseases.

[24]  J. Macdonald,et al.  Methotrexate for induction of remission in ulcerative colitis. , 2014, The Cochrane database of systematic reviews.

[25]  A. Ford,et al.  Mycophenolate mofetil therapy for refractory inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[26]  C. Mulder,et al.  Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[27]  B. Sands,et al.  Selective leukocyte apheresis for the treatment of inflammatory bowel disease. , 2007, Journal of clinical gastroenterology.

[28]  M. Clerici,et al.  Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease , 2007, Gut.

[29]  F. Wrba,et al.  6-Thioguanine Associated Nodular Regenerative Hyperplasia in Patients With Inflammatory Bowel Disease May Induce Portal Hypertension , 2007, The American Journal of Gastroenterology.

[30]  R. Leong,et al.  The use of tacrolimus in the treatment of inflammatory bowel disease , 2007, Expert opinion on drug safety.

[31]  W. Selby,et al.  Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. , 2007, Gastroenterology.

[32]  T. Ullman.  Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no"). , 2007, Gastroenterology.

[33]  M. A. Kamm,et al.  Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies , 2007, Alimentary pharmacology & therapeutics.

[34]  S. Ng,et al.  Medium‐term results of oral tacrolimus treatment in refractory inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[35]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  M. Vatn,et al.  Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia , 2007, Scandinavian journal of gastroenterology.

[37]  C. O'Morain,et al.  Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease , 2007, Scandinavian Journal of Gastroenterology.

[38]  J. Mate,et al.  The Role of Tacrolimus in Inflammatory Bowel Disease: A Systematic Review , 2006, Digestive Diseases and Sciences.

[39]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[40]  K. Herrlinger,et al.  Tacrolimus—finally! , 2006, Gut.

[41]  A. Akobeng.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Journal of pediatric gastroenterology and nutrition.

[42]  B. Wiedenmann,et al.  Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up , 2006, The American Journal of Gastroenterology.

[43]  W. Petritsch,et al.  6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party , 2006, Digestion.

[44]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[45]  A. Pineda.  Developments in the apheresis procedure for the treatment of inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[46]  G. Lichtenstein.  Trichuris suis Therapy for Active Ulcerative Colitis: A Randomized Controlled Trial , 2006 .

[47]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[48]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[49]  Joel V Weinstock,et al.  Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. , 2005, Gastroenterology.

[50]  A. Halverson,et al.  Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. , 2005, Gastroenterology.

[51]  D. Jewell,et al.  Oral methotrexate in ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.

[52]  Robert W. Summers,et al.  Vomiting in the recently anticoagulated patient , 2004, Gut.

[53]  A. Terano,et al.  Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[54]  M. Gassull,et al.  Granulocyteaphaeresis in steroid‐dependent inflammatory bowel disease: a prospective, open, pilot study , 2004, Alimentary pharmacology & therapeutics.

[55]  P. Gionchetti,et al.  Problematic proctitis and distal colitis , 2004 .

[56]  Tatsuo Tanaka,et al.  Adsorptive Granulocyte and Monocyte Apheresis versus Prednisolone in Patients with Corticosteroid-Dependent Moderately Severe Ulcerative Colitis , 2004, Digestion.

[57]  M. A. Kamm,et al.  Azathioprine dose escalation in inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[58]  H. Ogata,et al.  Granulocytapheresis Is Useful as an Alternative Therapy in Patients with Steroid-refractory or -dependent Ulcerative Colitis , 2004, Inflammatory Bowel Diseases.

[59]  P. Rutgeerts,et al.  Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis , 2004, Inflammatory bowel diseases.

[60]  P. Lakatos,et al.  Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. , 2004, World journal of gastroenterology.

[61]  T. Yoshikawa,et al.  Immunomodulatory Effects of Granulocyte and Monocyte Adsorption Apheresis as a Treatment for Patients with Ulcerative Colitis , 2002, Digestive Diseases and Sciences.

[62]  P. Gionchetti,et al.  Review article: problematic proctitis and distal colitis. , 2004, Alimentary pharmacology & therapeutics.

[63]  J. Papadimitriou,et al.  Histologic Features of Mycophenolate Mofetil-Related Colitis: A Graft-Versus-Host Disease-Like Pattern , 2003, International journal of surgical pathology.

[64]  W. Petritsch,et al.  Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[65]  Christopher F. Martin,et al.  Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. , 2003, Gastroenterology.

[66]  J. Belaiche,et al.  Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine , 2003, Alimentary pharmacology & therapeutics.

[67]  S. Targan,et al.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.

[68]  R. Playford,et al.  Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. , 2003, The New England journal of medicine.

[69]  A. Axon,et al.  Mycophenolate mofetil in refractory inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[70]  B. Wiedenmann,et al.  Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[71]  Y. Kohgo,et al.  Leukocytapheresis for treatment of IBD. , 2002, Journal of gastroenterology.

[72]  K. Fellermann,et al.  Response of Refractory Colitis to Intravenous or Oral Tacrolimus (FK506) , 2002, Inflammatory bowel diseases.

[73]  R. Modigliani,et al.  An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[74]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[75]  D. Jewell,et al.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review , 2002, Gut.

[76]  C. Hawkey,et al.  Toxicity of Mycophenolate Mofetil in Patients with Inflammatory Bowel Disease , 2002, Inflammatory bowel diseases.

[77]  H. Lochs,et al.  Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease , 2002, Gut.

[78]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[79]  A. Pisani,et al.  Oral tacrolimus long‐term therapy in patients with Crohn’s disease and steroid resistance , 2001, Alimentary pharmacology & therapeutics.

[80]  T. Dassopoulos,et al.  Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature , 2001, Annals of medicine.

[81]  A. Baldwin,et al.  Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. , 2001, The Journal of biological chemistry.

[82]  A. Griffiths,et al.  Enteral nutritional therapy for inducing remission of Crohn's disease. , 2001, The Cochrane database of systematic reviews.

[83]  P. Martreau.  [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.

[84]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[85]  G. Greenberg,et al.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease , 2000 .

[86]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[87]  K. Izeradjene,et al.  Mechanisms of action of methotrexate. , 2000, Immunopharmacology.

[88]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[89]  D. Macintosh,et al.  A meta-analysis of antimycobacterial therapy for Crohn's disease , 2000, American Journal of Gastroenterology.

[90]  D. Macintosh,et al.  Anti-tuberculous therapy for maintaining remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.

[91]  S. Hanauer,et al.  Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. , 1999, Gastroenterology.

[92]  S. Targan,et al.  An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. , 1999, Gastroenterology.

[93]  G. Radford-Smith,et al.  Mycophenolate mofetil in IBD patients , 1999, The Lancet.

[94]  D. Podolsky,et al.  Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. , 1999, Hepato-gastroenterology.

[95]  J. Mary,et al.  A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease , 1999, American Journal of Gastroenterology.

[96]  K. Fellermann,et al.  Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) , 1998, American Journal of Gastroenterology.

[97]  L. Genestier,et al.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. , 1998, The Journal of clinical investigation.

[98]  G. Radford-Smith,et al.  Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF) , 1998, Australian and New Zealand journal of medicine.

[99]  J. Shupack,et al.  Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. , 1997, Journal of the American Academy of Dermatology.

[100]  A. Lavy,et al.  Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.

[101]  A. Messori,et al.  Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. , 1996, Scandinavian journal of gastroenterology.

[102]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[103]  E. Cabré,et al.  How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. , 1995, JPEN. Journal of parenteral and enteral nutrition.

[104]  G. Fick,et al.  Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.

[105]  A. Griffiths,et al.  Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. , 1995, Gastroenterology.

[106]  D. Present,et al.  Methotrexate for Crohn's disease. , 1995, The New England journal of medicine.

[107]  G. Fick,et al.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.

[108]  D. Faulds,et al.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. , 1993, Drugs.

[109]  K. Batts,et al.  Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. , 1993, The American journal of gastroenterology.

[110]  S. Hanauer,et al.  Double blind, placebo controlled trial of metronidazole in Crohn's disease. , 1991, Gut.

[111]  G. Crabtree,et al.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A , 1991, Nature.

[112]  A. Forbes,et al.  Safety and efficacy of acetarsol suppositories in unresponsive proctitis , 1989, Alimentary pharmacology & therapeutics.

[113]  P. Velio,et al.  TREATMENT OF CHRONIC PROCTOSIGMOIDITIS WITH CYCLOSPORIN ENEMAS , 1989, The Lancet.

[114]  V. Binder,et al.  TREATMENT OF REFRACTORY ULCERATIVE COLITIS WITH CYCLOSPORIN ENEMAS , 1989, The Lancet.

[115]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[116]  R. Peto.  CANCER, CHOLESTEROL, CAROTENE, AND TOCOPHEROL , 1981, The Lancet.

[117]  Burr Ml,et al.  Droughts and diarrhoea. , 1980 .